NASDAQ:GRNV

GreenVision Acquisition Competitors

$10.18

0.00 (0.00 %)

(As of 04/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$10.17

Now: $10.18▼

$10.19

50-Day Range

$10.10

MA: $10.17▼

$10.21

52-Week Range

$9.87

Now: $10.18▼

$11.55

Volume8,854 shs

Average Volume123,826 shs

Market Capitalization$73.17 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

GreenVision Acquisition (NASDAQ:GRNV) Vs. FMS, DVA, SHC, PGNY, TVTY, and TLMD

Should you be buying GRNV stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to GreenVision Acquisition, including Fresenius Medical Care AG & Co. KGaA (FMS), DaVita (DVA), Sotera Health (SHC), Progyny (PGNY), Tivity Health (TVTY), and SOC Telemed (TLMD).

GreenVision Acquisition vs. Fresenius Medical Care AG & Co. KGaA Stock

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and GreenVision Acquisition (NASDAQ:GRNV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and GreenVision Acquisition's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fresenius Medical Care AG & Co. KGaA	7.38%	10.62%	4.15%
GreenVision Acquisition	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Fresenius Medical Care AG & Co. KGaA and GreenVision Acquisition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius Medical Care AG & Co. KGaA	1	9	7	0	2.35
GreenVision Acquisition	0	0	0	0	N/A

Fresenius Medical Care AG & Co. KGaA presently has a consensus target price of $45.00, indicating a potential upside of 19.43%. Given Fresenius Medical Care AG & Co. KGaA's higher probable upside, equities research analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than GreenVision Acquisition.

Institutional and Insider Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Fresenius Medical Care AG & Co. KGaA and GreenVision Acquisition's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA	$19.58 billion	1.13	$1.34 billion	$2.53	14.89
GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than GreenVision Acquisition.

Summary

Fresenius Medical Care AG & Co. KGaA beats GreenVision Acquisition on 6 of the 7 factors compared between the two stocks.

GreenVision Acquisition vs. DaVita Stock

DaVita (NYSE:DVA) and GreenVision Acquisition (NASDAQ:GRNV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares DaVita and GreenVision Acquisition's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DaVita	7.32%	43.99%	5.27%
GreenVision Acquisition	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for DaVita and GreenVision Acquisition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1	3	1	0	2.00
GreenVision Acquisition	0	0	0	0	N/A

DaVita presently has a consensus target price of $114.60, indicating a potential upside of 5.89%. Given DaVita's higher probable upside, equities research analysts plainly believe DaVita is more favorable than GreenVision Acquisition.

Institutional and Insider Ownership

91.7% of DaVita shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. 1.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares DaVita and GreenVision Acquisition's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$11.39 billion	1.04	$810.98 million	$5.40	20.04
GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A

DaVita has higher revenue and earnings than GreenVision Acquisition.

Summary

DaVita beats GreenVision Acquisition on 8 of the 8 factors compared between the two stocks.

GreenVision Acquisition vs. Sotera Health Stock

Sotera Health (NYSE:SHC) and GreenVision Acquisition (NASDAQ:GRNV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Sotera Health and GreenVision Acquisition's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sotera Health	N/A	N/A	N/A
GreenVision Acquisition	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Sotera Health and GreenVision Acquisition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0	0	10	0	3.00
GreenVision Acquisition	0	0	0	0	N/A

Sotera Health presently has a consensus target price of $32.75, indicating a potential upside of 26.30%. Given Sotera Health's higher probable upside, equities research analysts plainly believe Sotera Health is more favorable than GreenVision Acquisition.

Institutional and Insider Ownership

67.7% of GreenVision Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Sotera Health and GreenVision Acquisition's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	N/A	N/A	N/A	N/A	N/A
GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Sotera Health beats GreenVision Acquisition on 2 of the 3 factors compared between the two stocks.

GreenVision Acquisition vs. Progyny Stock

Progyny (NASDAQ:PGNY) and GreenVision Acquisition (NASDAQ:GRNV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Progyny and GreenVision Acquisition's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Progyny	1.03%	7.43%	5.04%
GreenVision Acquisition	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Progyny and GreenVision Acquisition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0	0	6	0	3.00
GreenVision Acquisition	0	0	0	0	N/A

Progyny presently has a consensus target price of $38.8333, indicating a potential downside of 22.10%. Given Progyny's higher probable upside, equities research analysts plainly believe Progyny is more favorable than GreenVision Acquisition.

Valuation and Earnings

This table compares Progyny and GreenVision Acquisition's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$229.68 million	18.93	$-8,570,000.00	$0.11	453.18
GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A

GreenVision Acquisition has lower revenue, but higher earnings than Progyny.

Institutional and Insider Ownership

58.5% of Progyny shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. 33.3% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Progyny beats GreenVision Acquisition on 7 of the 8 factors compared between the two stocks.

GreenVision Acquisition vs. Tivity Health Stock

Tivity Health (NASDAQ:TVTY) and GreenVision Acquisition (NASDAQ:GRNV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Tivity Health and GreenVision Acquisition's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tivity Health	-47.44%	128.43%	6.11%
GreenVision Acquisition	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Tivity Health and GreenVision Acquisition, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tivity Health	1	2	5	0	2.50
GreenVision Acquisition	0	0	0	0	N/A

Tivity Health currently has a consensus price target of $22.1250, indicating a potential downside of 5.33%. Given Tivity Health's higher probable upside, research analysts clearly believe Tivity Health is more favorable than GreenVision Acquisition.

Earnings & Valuation

This table compares Tivity Health and GreenVision Acquisition's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tivity Health	$1.13 billion	1.02	$-286,820,000.00	$2.02	11.57
GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A

GreenVision Acquisition has lower revenue, but higher earnings than Tivity Health.

Institutional & Insider Ownership

91.6% of Tivity Health shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. 11.8% of Tivity Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Tivity Health beats GreenVision Acquisition on 7 of the 8 factors compared between the two stocks.

GreenVision Acquisition vs. SOC Telemed Stock

SOC Telemed (NASDAQ:TLMD) and GreenVision Acquisition (NASDAQ:GRNV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares SOC Telemed and GreenVision Acquisition's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SOC Telemed	N/A	N/A	N/A
GreenVision Acquisition	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for SOC Telemed and GreenVision Acquisition, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOC Telemed	0	1	5	0	2.83
GreenVision Acquisition	0	0	0	0	N/A

SOC Telemed currently has a consensus price target of $11.40, indicating a potential upside of 67.89%. Given SOC Telemed's higher probable upside, research analysts clearly believe SOC Telemed is more favorable than GreenVision Acquisition.

Earnings & Valuation

This table compares SOC Telemed and GreenVision Acquisition's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOC Telemed	N/A	N/A	$20,000.00	N/A	N/A
GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A

Institutional & Insider Ownership

20.7% of SOC Telemed shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

SOC Telemed beats GreenVision Acquisition on 2 of the 3 factors compared between the two stocks.